65,437 trials
Reversal of Neuromuscular Blockade
Primary: Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events — 1.0; 1.9; 7.4; 7.8 Percentage of participants — p=0.026
Periapical Periodontitis · Bacterial Infections
Primary: Metabolic Activity of Persistent Bacteria — 4.748; 2.57; 2.614; 4.0008 RNA/DNA ratio
Glucose Intolerance
Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380
Lymphoma, Follicular
Primary: Overall Response Rate (ORR) at Week 28 — 66.3; 70.6 percentage of participants
Acute Myeloid Leukemia (AML)
Primary: Overall Survival — 94.0; 170.0 Days — p=0.4221
Carpal Tunnel Syndrome, Susceptibility to
Primary: Numerical Pain Rating Scale (NRS Pain) — 0.01; .17; .30; .005 score on a scale — p=0.48
Airway Morbidity · Anaesthesia
Primary: Airway Seal Pressure Values — 31.20; 27.58; 30.10; 28.76 cm H2O
Drug Interaction Potentiation
Primary: Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax) — 12.4; 13.0 ng/mL
Metabolic Syndrome X
Primary: Total Insulin Sensitivity — 4.2; 2.6 index — p=0.003
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
Malignant Solid Tumor
Primary: Cmax at Single Dose — 24.4; 68.8; 192; 214 μg/mL
Pain
Primary: Change From Pre-Treatment in TMJ Loading Pain Rating at 12 Weeks — -1; -2 units on a scale
Myopia
Primary: Percentage of Eyes With Absolute Lens Rotation ≤ 10 Degrees. — 489; 426 eyes
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target…